On January 23, 2026, Robert B. Ford, Abbott’s Chairman and CEO, acquired 18,800 common shares at approximately $107.13 each, raising his total stake to 216,203 shares. This transaction underscores senior management’s conviction in the company’s long-term trajectory, especially as the stock has retraced from its 52-week high. Such insider buying is often viewed by market participants as a positive indicator, suggesting executives believe current valuations understate the firm’s growth prospects.

In the fourth quarter of fiscal 2025, Abbott generated $11.5 billion in revenue, falling short of the consensus estimate of $11.8 billion. The nutrition segment bore the brunt of higher manufacturing costs, leading to price increases that weighed on unit demand. Nevertheless, adjusted diluted EPS rose by 12% year-over-year, in line with analyst forecasts. The medical devices division drove the quarter’s outperformance, with continuous glucose monitoring systems delivering double-digit growth and offsetting softness elsewhere.

Management has raised its full-year targets, projecting 6.5%–7.5% organic sales growth for 2026, up from 5.5% growth in 2025. The company also reiterated expectations for adjusted EPS of $5.55 to $5.80, reflecting roughly 10% year-over-year expansion at the mid-point. These forecasts rest on continued roll-outs of next-generation medical devices and a normalization in the nutrition business as cost efficiencies are realized and pricing stabilizes.

Abbott is on track to complete its acquisition of Exact Sciences in the second quarter of 2026. This transaction is expected to introduce a new cancer-detection vertical, leveraging Exact Sciences’ proprietary early-screening platforms. Management anticipates that the deal will be accretive to sales growth and margins within the first full year post-close, further diversifying the company’s diagnostic portfolio and bolstering long-term revenue expansion.